Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ayman
NCT05774639: Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria	Completed	3	600	US, RoW	Omalizumab Injection, ADL-018, Xolair Prefilled Syringe	Kashiv BioSciences, LLC, COD Research Private Ltd	Chronic Idiopathic Urticaria	10/24	12/24